Introduction Formal Biosimilar Biological Product Development (BPD) Meetings serve as an essential regulatory bridge between sponsors and the United States […]
Introduction Quality control of Oligonucleotide Starting Materials involves systematic analytical characterization, impurity quantification, and physical validation of phosphoramidites and functionalized
Introduction: A Peptide Assay Discrepancy Investigation is a systematic review that explains why two analytical results for the same peptide
Introduction Amino Acid Analysis by HPLC determines the precise amino acid composition and absolute peptide content of biopharmaceutical preparations through
Introduction Semaglutide Amino Acid Analysis is an essential quantitative characterization technique used to determine the precise stoichiometric molar ratios of
Introduction The USP Risk Assessment Explained framework provides biopharmaceutical manufacturers with a standardized, science-based methodology for classifying polymeric manufacturing components
Introduction Evaluating Synthetic vs Recombinant Manufacturing for long peptides and small proteins requires balancing sequence length, non-canonical modifications, scale-up economics,
Introduction A specialized Subvisible and Visible Particle Testing Service provides essential physical characterization and quality control data needed to establish
Subvisible and Visible Particle Testing Service for Biosimilars: MFI, RMM, and USP <788> Read More »
Introduction: Biologics, including monoclonal antibodies (mAbs), recombinant proteins, enzymes, fusion proteins, and biosimilars, are structurally complex medicines whose quality depends
PTM and Glycosylation Analysis Services for Biologics Read More »
Introduction Therapeutic oligonucleotide manufacturing depends on Phosphoramidite Solid-Phase Synthesis to assemble custom single-stranded and double-stranded nucleic acid sequences at scales
